Pharming Group
PHAR
3 hedge funds and large institutions have $296K invested in Pharming Group in 2023 Q1 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 2 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
9% less capital invested
Capital invested by funds: $325K → $296K (-$29.5K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CPA
Cowen Prime Advisors
New York
|
+$10.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$52.4K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$4.67K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CPA
1
Cowen Prime Advisors
New York
| $250K | +$10.7K | +850 | +4% |
|
|
2
Morgan Stanley
New York
| $33.8K | -$52.4K | -4,149 | -62% |
|
|
3
UBS Group
Zurich,
Switzerland
| $11.9K | -$4.67K | -370 | -30% |
|
PHAR Hedge Fund Activity: Q1 2023 in Review
3 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Pharming Group (PHAR) for Q1 2023, worth a combined $296K — down 9.1% from $325K a quarter earlier.
Fund positioning in PHAR was balanced in Q1 2023: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 2 trimmed.
The largest buyer was Cowen Prime Advisors, adding an estimated $10.7K. The largest seller was Morgan Stanley, cutting an estimated $52.4K.
- 3 institutional investors held Pharming Group (PHAR) as of Q1 2023, unchanged from Q4 2022.
- Funds reported $296K of Pharming Group stock for Q1 2023, down 9.1% quarter-over-quarter.
- 0 funds opened new Pharming Group positions in Q1 2023 and 0 closed out.
- The largest Pharming Group buyer in Q1 2023 was Cowen Prime Advisors, an estimated $10.7K added.
- The largest Pharming Group seller in Q1 2023 was Morgan Stanley, an estimated $52.4K sold.
Based on aggregated 13F filings for Q1 2023.